SynthesisBMC nephrology2026
Comparison of the effects of non-calcium and calcium-based phosphate binders on fibroblast growth factor-23 levels in patients with CKD-mineral and bone disorder: a meta-analysis of randomized controlled trials.
Synthesis in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhosphate binders are used to manage hyperphosphatemia in patients with chronic kidney disease-mineral and bone disorder (CKD-MBD) and may influence fibroblast growth factor 23 (FGF-23), a biomarker associated with disease progression and mortality. However, the comparative effects of calcium-based phosphate binders (CPBs) and non-calcium-based phosphate binders (NCPBs) on FGF-23 levels remain unclear. We conducted a meta-analysis of randomized controlled trials to compare the effects of NCPBs and CPBs on FGF-23 levels in patients with CKD-MBD with hyperphosphatemia.
methodsA systematic search of PubMed, EMBASE, and the Cochrane Library was performed for studies published up to August 2024. Only randomized controlled trials were eligible; non-randomized controlled trials, studies with overlapping patient populations, pediatric or animal studies, and trials without quantitative FGF-23 outcomes were excluded. Language restrictions were not imposed. Data were synthesized as standardized mean differences using a random-effects model, and the risk of bias was assessed using the Cochrane Risk of Bias 2 tool.
resultsEleven randomized controlled trials involving 791 patients were included. Overall, NCPBs were associated with a greater reduction in FGF-23 levels compared with CPBs (standardized mean difference −0.56, 95% confidence interval −0.95 to −0.17, p = 0.005). Subgroup analyses suggested consistent trends across binder types (sevelamer and lanthanum), dialysis status, and treatment duration. However, the subgroup differences were not statistically significant, and heterogeneity remained substantial in several subgroups, indicating that these findings should be interpreted with caution.
conclusionsIn CKD-MBD patients with hyperphosphatemia, NCPBs were associated with greater reductions in FGF-23 levels compared with CPBs. The subgroup results suggested possible trends by binder type, CKD category, and treatment duration. However, given the heterogeneity and lack of statistically significant subgroup differences, these findings should be considered hypothesis-generating. Further well-designed trials are needed to confirm these results and clarify the underlying mechanisms and clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.